← Back to patent-cliff list
LY-3537021
Tier C — Watch / tradeLY-3537021
Eli Lilly and Company
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GIPR
Indications (approved)：Chemotherapy-induced nausea and vomiting, Nausea, 呕吐, Drug-related adverse effects and reactions, Neoplasm, Type 2 diabetes
Regional status
US
Phase II
2025-11-28
EU
Phase II
2025-11-28
China
Phase II
2025-11-28
Japan
Phase II
2025-11-28
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of LY-3537021?
Approved indications include: Chemotherapy-induced nausea and vomiting, Nausea, 呕吐, Drug-related adverse effects and reactions, Neoplasm, Type 2 diabetes.
When does the LY-3537021 patent expire?
No public expiry year is available for LY-3537021 yet; this page updates once verified.
How do I get a quote for LY-3537021 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30